Heart study tests Lower-Dose blood thinner and new stents for better safety

NCT ID NCT02193971

Completed Disease control Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at over 3,400 people with acute coronary syndrome (a heart attack or unstable angina) who received a stent to open blocked arteries. Researchers compared two types of stents (biostable vs. biodegradable polymer) and two doses of the blood thinner prasugrel (5 mg vs. 10 mg daily). The goal was to see if the newer stents and lower dose are as effective and safer than the standard options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Prasugrel (blood thinner) and drug-eluting stents (medical devices)
What this could lead to: If successful, this could show that a lower dose of prasugrel is just as safe and effective as the standard dose, and that one type of stent is better than another for heart patients.
What could go wrong: This is a completed Phase 4 trial, so results are already in. However, the findings may not apply to all heart patients, and individual risks like bleeding or stent complications remain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE CORONARY SYNDROME

Contacts and locations

Locations

Seoul National University Hospital

Seoul, 110-744, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.